Revotar presents significant final results from 4 weeks Phase II COPD study
(Thomson Reuters ONE) -
Revotar Biopharmaceuticals AG /
Revotar presents significant final results from 4 weeks Phase II COPD study
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
BERLIN/Hennigsdorf (Germany), May 18, 2011 - Revotar Biopharmaceuticals AG, a
biotech company focusing on the development of small molecule anti-inflammatory
drug candidates, today announced the final data (final TLFs) of its Phase II
COPD study. The data confirm the already outlined positive top-line results
released on March 30, 2011. The primary endpoint IL-8 was met with high
statistical significance. "Our recent results confirm the broad and significant
anti-inflammatory effect with clear indications on improvement of lung function
in COPD patients (GOLD II-III)", emphasized Dr. Martin Poehlchen, CEO of the
company.
The company attends the ongoing International Conference of the American
Thoracic Society (ATS). The clinical investigator Prof. Helgo Magnussen
(Großhansdorf, Germany) and his team present the latest published data[1] of a
previous phase IIa study with Bimosiamose (ozone provocation study) in healthy
volunteers.
"We will discuss our positive data and the future clinical development with
international key opinion leaders at the ATS conference in Denver", said Prof.
Wolfgang Meyer-Sabellek, CMO of Revotar.
[1] Kirsten A, Watz H, Kretschmar G, Pedersen F, Bock D, Meyer-Sabellek W,
Magnussen H.; Efficacy of the pan-selectin antagonist Bimosiamose on ozone-
induced airway inflammation in healthy subjects - A double blind, randomized,
placebo-controlled, cross-over clinical trial; Pulm Pharmacol Ther. 2011 Apr
14. [Epub ahead of print]
About COPD
Chronic Obstructive Pulmonary Disease (COPD) comprises several serious
conditions affecting the lung. According to the WHO, COPD is affecting more than
210 million people worldwide, of which about 80 million people suffer from
moderate to severe forms of the disease. More than 3 million people died of COPD
in 2005, which corresponds to 5% of all deaths globally. The WHO predicts that
COPD will become the third leading cause of death worldwide by 2030. In 2009,
the global COPD market recorded sales of approximately 10 billion US-$.
About Revotar Biopharmaceutical AG
Revotar develops innovative drugs for inflammatory indications such as chronic
obstructive pulmonary disease (COPD), acute lung injury (ALI) and asthma. Its
lead candidate Bimosiamose, a pan-selectin antagonist, has already passed
several clinical phase I and phase IIa trials in COPD, asthma and psoriasis with
a good safety and efficacy profile in over 300 patients and volunteers.
Furthermore, Revotar has two preclinical programs addressing respiratory and
other inflammatory diseases.
Contact Address:
Dr. Martin Pöhlchen, CEO
Revotar Biopharmaceuticals AG
Neuendorfstr. 24a
D-16761 Hennigsdorf / Germany
Phone: +49-3302-2025010
Fax: +49-3302-2025030
Email:info(at)revotar.com
www.revotar.com
--- End of Message ---
Revotar Biopharmaceuticals AG
Neuendorfstr. 24a Hennigsdorf Germany
Press Release (PDF):
http://hugin.info/143207/R/1517022/453457.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Revotar Biopharmaceuticals AG via Thomson Reuters ONE
[HUG#1517022]
Unternehmensinformation / Kurzprofil:
Datum: 18.05.2011 - 18:20 Uhr
Sprache: Deutsch
News-ID 54800
Anzahl Zeichen: 4291
contact information:
Town:
Hennigsdorf
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 234 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Revotar presents significant final results from 4 weeks Phase II COPD study"
steht unter der journalistisch-redaktionellen Verantwortung von
Revotar Biopharmaceuticals AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
